RxDoctor Payments Data

Peter Dahlberg

Psychiatric/Mental Health · Arvada, CONPI 1013311216

Payments from drug & device makers

$1,238in general payments, 2019–2025

Across 50 payments — averaging $24.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$478
  • Teva Pharmaceuticals USA, Inc.$241
  • Supernus Pharmaceuticals, Inc.$175
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$103
  • Axsome Therapeutics, Inc.$71
  • Corium, LLC$44
  • plus $125 from 6 others

What the payments were for

  • Food & beverage$1,13191%
  • Education$1079%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,238 in reported general payments places this provider in the 80th percentile of 873 psychiatric/mental health providers in Colorado.

See all psychiatric/mental health providers in Colorado

Medicare billing

Part B allowed, 2024
$6,759
Medicare patients
18
Services billed
80

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate11$122,367
VraylarCariprazine Hcl14$20,130
TrintellixVortioxetine Hydrobromide14$7,039
BelsomraSuvorexant11$5,032
Duloxetine Hcl109$1,306
Desvenlafaxine Succinate ErDesvenlafaxine Succinate32$963
Bupropion XlBupropion Hcl68$958
Ziprasidone Hcl32$931
Clonazepam91$847
Clozapine12$781
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine27$754
Gabapentin54$613
Buspirone Hcl65$592
Aripiprazole34$506
Alprazolam62$373

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$27$122,36711 claims
Almatica Pharma LLCSertraline Hcl$16$7617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 873 psychiatric/mental health providers in Colorado.

Other psychiatric/mental health in Arvada

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →